JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Sanofi

Chiusa

51.62 4.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

51.44

Massimo

51.86

Metriche Chiave

By Trading Economics

Entrata

2.1B

3.9B

Vendite

129M

11B

P/E

Media del settore

16.577

37.461

EPS

0.91

Rendimento da dividendi

7.74

Margine di Profitto

36.702

Dipendenti

82,878

EBITDA

-881M

1.9B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+21.03% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

7.74%

2.33%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.4B

123B

Apertura precedente

47.55

Chiusura precedente

51.62

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Sanofi Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ott 2025, 08:29 UTC

Utili

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24 ott 2025, 07:00 UTC

Utili

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

1 ott 2025, 08:54 UTC

I principali Market Mover

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

4 set 2025, 08:58 UTC

I principali Market Mover

Sanofi Shares Sink as Experimental Drug Results Disappoint

31 lug 2025, 06:00 UTC

Utili

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

24 ott 2025, 08:21 UTC

Discorsi di Mercato
Utili

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 ott 2025, 07:56 UTC

Discorsi di Mercato
Utili

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24 ott 2025, 05:30 UTC

Utili

Sanofi 3Q Adj EPS EUR2.91

24 ott 2025, 05:30 UTC

Utili

Sanofi Backs 2025 View

24 ott 2025, 05:30 UTC

Utili

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

24 ott 2025, 05:30 UTC

Utili

Sanofi 3Q Business Net Profit at EUR3.55B

24 ott 2025, 05:30 UTC

Utili

Analysts Saw Sanofi 3Q Adjusted EPS at EUR2.70

24 ott 2025, 05:30 UTC

Utili

Sanofi: Dupixent Sales Up 26% to EUR4.16B

24 ott 2025, 05:30 UTC

Utili

Sanofi 3Q Net Pft EUR2.80B

24 ott 2025, 05:30 UTC

Utili

Analysts Saw Sanofi 3Q Net Sales at EUR12.29B

24 ott 2025, 05:30 UTC

Utili

Sanofi 3Q Sales EUR12.43B

6 ott 2025, 08:15 UTC

Discorsi di Mercato

Sanofi's Profitability Stronger Than It Looks -- Market Talk

3 ott 2025, 14:10 UTC

Discorsi di Mercato

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

1 ott 2025, 07:53 UTC

Discorsi di Mercato

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

5 set 2025, 08:24 UTC

Discorsi di Mercato

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 set 2025, 06:55 UTC

Discorsi di Mercato

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

6 ago 2025, 05:02 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Completes the Acquisition of Vigil Neuroscience

6 ago 2025, 05:00 UTC

Acquisizioni, Fusioni, Takeovers

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 ago 2025, 13:16 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 lug 2025, 08:15 UTC

Discorsi di Mercato
Utili

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 lug 2025, 05:56 UTC

Discorsi di Mercato
Utili

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 lug 2025, 05:30 UTC

Utili

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 lug 2025, 05:30 UTC

Utili

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 lug 2025, 05:30 UTC

Utili

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

Confronto tra pari

Modifica del prezzo

Sanofi Previsione

Obiettivo di Prezzo

By TipRanks

21.03% in crescita

Previsioni per 12 mesi

Media 62.5 USD  21.03%

Alto 67 USD

Basso 58 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

51.665 / 52.38Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat